Over the Counter Medications Updated During November 2022, From Newest to Oldest, Page 3

Page 3 of 302 « 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

AirDefender Daily Antibacterial Sanitizing Mist (BENZALKONIUM CHLORIDE)

Help reduce bacteria contact that potentially can cause disease. Warnings: For external use only. Do not use on open skin wounds. Keep out of eyes. In case of contact with eyes, rinse eye…

Airdefender International Company Limited30 November 2022

Te-Fu Recovery Massage (Menthol, Methyl Salicylate)

If condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days, discontinue use of product and consult a physician. Warnings: For external…

Wasatch Product Development30 November 2022

1438 DynaSoap (Antibacterial Hand Soap)

Cleaning and antiseptic cleansing of hands and skin. Warnings: For external use only. When using this product: Avoid contact with eyes. In case of contact, flush with water. Stop use and…

Dynarex Corporation30 November 2022

Hand Sanitizer Wipes Pack with Plastic Dispensing Lid

For hand sanitizing to decrease bacteria on the skin. Warnings: For external use only. Flammable Keep away from fire or flame. When using this product: Avoid contct with eyes. In case of…

Dynarex30 November 2022

SPF 50 Moisturizing Sunscreen Broad Spectrum (Octinoxate, Zinc Oxide)

Stop use and ask a doctor if rash occurs. Warnings: For External Use Only. Do not use on damaged or broken skin. When using this product keep out of eyes. Rinse with water to remove…

GATE THERAPEUTICS30 November 2022

Page 3 of 302 « 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

FDA Medwatch

Antiseizure Medicines Keppra, Keppra XR, Elepsia XR, Spritam (levetiracetam) and Onfi, Sympazan (clobazam): Drug Safety Communication – FDA Warns of Rare but Serious Drug Reaction
Mon, 27 Nov 2023. The FDA is warning that the antiseizure medicines can cause a rare but serious reaction, called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), that can be life-threatening if not diagnosed and treated quickly.
BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies: FDA Safety Communication – FDA Investigating Serious Risk of T-cell Malignancy
Mon, 27 Nov 2023. The FDA has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.

OTCLabels

Medication Sections

Medication Information by RSS

About

Our database comes directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. OTCLabels.com provides the full over the counter products subset of the FDA's repository. Medication information provided here is not intended as a substitute for direct consultation with a qualified health professional.